https://www.selleckchem.com/products/kn-62.html
Transcriptomic analysis of nasal epithelial samples demonstrated that treatment with the combination of SCIT/tezepelumab, but neither monotherapy, caused persistent downregulation of a gene network related to type 2 inflammation that was associated with improvement in NAC responses. Inhibition of TSLP augments the efficacy of SCIT during therapy and may promote tolerance after a 1-year course of treatment. (ClinicalTrials.gov NCT02237196). Inhibition of TSLP augments the efficacy of SCIT during therapy and may promote tolerance after a 1-
Like
Comment
Share
